New COPD Therapy Suggested in Study of Innate Lymphoid Cells in Lung Inflammation

New COPD Therapy Suggested in Study of Innate Lymphoid Cells in Lung Inflammation

A research team discovered that innate lymphoid cells need certain nutrients to function, a finding that may lead to new treatments for patients with chronic obstructive pulmonary disease (COPD) and other inflammatory lung disorders.

Researchers have long known that innate lymphoid cells play a vital role in promoting inflammatory reactions in the lung. The research team at Weill Cornell Medicine were studying the cells when they discovered that levels of the enzyme arginase 1 (Arg1) were increased in mouse and human innate lymphoid cells during both acute and chronic inflammation.

To explore the consequences of this finding, the team studied mutant mice lacking Arg1 only in the innate lymphoid cells. In the study, Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation, researchers exposed the mice to papain, a substance found in the papaya plant and often used to elicit allergic responses followed by inflammation. Findings, published in the journal Nature Immunology, revealed that the Arg1-lacking mice neither developed an allergic reaction to papain nor showed any signs of inflammation.

Arg1 is crucial for breaking down the amino acid arginine into smaller nutrients that the cell can use for energy consumption. The team proved that the lack of Arg1 — leading to cell starvation — prevented the inflammatory response. Deprived of essential nutrients, the cells did not expand in numbers and could not function properly.

“These findings are very exciting and propel us to look deeper into how the immune system is regulated in the context of health and chronic inflammatory diseases,” said the study’s senior author, Dr. David Artis, in a press release.

“This report gives us new mechanistic insight to understand how we might be able to design more selective drugs that specifically target innate lymphoid cells to treat a range of allergic diseases,” Dr. Artis, also the director of the Jill Roberts Institute for Research in Inflammatory Bowel Disease and the Michael Kors Professor of Immunology at Weill Cornell Medicine, added.

To explore the clinical relevance of the finding, the team also analyzed Arg1 expression in lung tissue samples from patients with COPD, as well as from patients with another inflammatory lung disease, idiopathic pulmonary fibrosis. Arg1 was also similarly expressed by the innate lymphoid cells in these tissues.

“While these are still early days in this research, our patient-based analysis, coupled with our mouse model studies, suggests altering Arginase-1 metabolism within these innate immune cells may offer a therapeutic target for multiple inflammatory diseases,” concluded Dr. Laurel Monticelli, the study’s first author.

One comment

  1. kostis ponti says:

    I hope this can be the way to treat COPD successfully. We need positive new treatments. There has not been any new treatments in many years. It is very depressing not having a hopeful way to treat it. I hope we see a quick development in this to help us with COPD. We need better treatment for this awful illness.

Leave a Comment

Your email address will not be published. Required fields are marked *